Literature DB >> 27933965

First Structure-Activity Relationship of 17β-Hydroxysteroid Dehydrogenase Type 14 Nonsteroidal Inhibitors and Crystal Structures in Complex with the Enzyme.

Florian Braun1, Nicole Bertoletti1, Gabriele Möller2, Jerzy Adamski2,3,4, Torsten Steinmetzer1, Mohamed Salah5, Ahmed S Abdelsamie5, Chris J van Koppen5, Andreas Heine1, Gerhard Klebe1, Sandrine Marchais-Oberwinkler1.   

Abstract

17β-HSD14 belongs to the SDR family and oxidizes the hydroxyl group at position 17 of estradiol and 5-androstenediol using NAD+ as cofactor. The goal of this study was to identify and optimize 17β-HSD14 nonsteroidal inhibitors as well as to disclose their structure-activity relationship. In a first screen, a library of 17β-HSD1 and 17β-HSD2 inhibitors, selected with respect to scaffold diversity, was tested for 17β-HSD14 inhibition. The most interesting hit was taken as starting point for chemical modification applying a ligand-based approach. The designed compounds were synthesized and tested for 17β-HSD14 inhibitory activity. The two best inhibitors identified in this study have a very high affinity to the enzyme with a Ki equal to 7 nM. The strong affinity of these inhibitors to the enzyme active site could be explained by crystallographic structure analysis, which highlighted the role of an extended H-bonding network in the stabilization process. The selectivity of the most potent compounds with respect to 17β-HSD1 and 17β-HSD2 is also addressed.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27933965     DOI: 10.1021/acs.jmedchem.6b01436

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

Review 1.  Virtual screening applications in short-chain dehydrogenase/reductase research.

Authors:  Katharina R Beck; Teresa Kaserer; Daniela Schuster; Alex Odermatt
Journal:  J Steroid Biochem Mol Biol       Date:  2017-03-09       Impact factor: 4.292

2.  Association of Coding Variants in Hydroxysteroid 17-beta Dehydrogenase 14 (HSD17B14) with Reduced Progression to End Stage Kidney Disease in Type 1 Diabetes.

Authors:  Josyf C Mychaleckyj; Erkka Valo; Takaharu Ichimura; Tarunveer S Ahluwalia; Christian Dina; Rachel G Miller; Ivan G Shabalin; Beata Gyorgy; JingJing Cao; Suna Onengut-Gumuscu; Eiichiro Satake; Adam M Smiles; Jani K Haukka; David-Alexandre Tregouet; Tina Costacou; Kristina O'Neil; Andrew D Paterson; Carol Forsblom; Hillary A Keenan; Marcus G Pezzolesi; Marlon Pragnell; Andrzej Galecki; Stephen S Rich; Niina Sandholm; Ronald Klein; Barbara E Klein; Katalin Susztak; Trevor J Orchard; Ron Korstanje; George L King; Samy Hadjadj; Peter Rossing; Joseph V Bonventre; Per-Henrik Groop; James H Warram; Andrzej S Krolewski
Journal:  J Am Soc Nephrol       Date:  2021-07-14       Impact factor: 14.978

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.